| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
455 Stock Overview
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.
Tianda Pharmaceuticals Competitors
Â
Â
Â
Â
Â
Â
Â
Â
Â
Â
Â
Â
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.20 |
| 52 Week High | HK$0.36 |
| 52 Week Low | HK$0.16 |
| Beta | 0.60 |
| 1 Month Change | 4.61% |
| 3 Month Change | -8.93% |
| 1 Year Change | -10.53% |
| 3 Year Change | -9.74% |
| 5 Year Change | -41.71% |
| Change since IPO | -65.13% |
Recent News & Updates
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Shareholder Returns
| 455 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 9.1% | 6.8% | 1.2% |
| 1Y | -10.5% | -44.5% | -23.3% |
Return vs Industry: 455 exceeded the Hong Kong Pharmaceuticals industry which returned -44.5% over the past year.
Return vs Market: 455 exceeded the Hong Kong Market which returned -23.3% over the past year.
Price Volatility
| 455 volatility | |
|---|---|
| 455 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 455 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 455's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 714 | Alan Fang | https://www.tiandapharma.com |
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese medicines, chemical drugs, biological and health products, and medical appliances covering the area of cardio-cerebrovascular, pediatric, flu and respiratory, anti-infection, detoxification, anti-cancer, and others. The company offers its health products under the Herb Valley and Tuokang brands.
Tianda Pharmaceuticals Fundamentals Summary
| 455 fundamental statistics | |
|---|---|
| Market Cap | HK$438.61m |
| Earnings (TTM) | -HK$29.54m |
| Revenue (TTM) | HK$523.49m |
0.8x
P/S Ratio-14.9x
P/E RatioIs 455 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 455 income statement (TTM) | |
|---|---|
| Revenue | HK$523.49m |
| Cost of Revenue | HK$277.90m |
| Gross Profit | HK$245.59m |
| Other Expenses | HK$275.13m |
| Earnings | -HK$29.54m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Jun 29, 2022
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 46.91% |
| Net Profit Margin | -5.64% |
| Debt/Equity Ratio | 19.3% |
How did 455 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield-19%
Payout RatioValuation
Is 455 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 455?
Other financial metrics that can be useful for relative valuation.
| What is 455's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | HK$438.61m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -22.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 455's PS Ratio compare to its peers?
| 455 PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x |
Price-To-Sales vs Peers: 455 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does 455's PE Ratio compare vs other companies in the Hong Kong Pharmaceuticals Industry?
Price-To-Sales vs Industry: 455 is good value based on its Price-To-Sales Ratio (0.8x) compared to the Hong Kong Pharmaceuticals industry average (1.6x)
Price to Sales Ratio vs Fair Ratio
What is 455's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 455's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 455 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 455 (HK$0.2) is trading above our estimate of fair value (HK$0.05)
Significantly Below Fair Value: 455 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 455's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Tianda Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
5.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianda Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Tianda Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Tianda Pharmaceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Tianda Pharmaceuticals performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-73.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 455 is currently unprofitable.
Growing Profit Margin: 455 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 455 is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.
Accelerating Growth: Unable to compare 455's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 455 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: 455 has a negative Return on Equity (-3.65%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Tianda Pharmaceuticals's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 455's short term assets (HK$577.4M) exceed its short term liabilities (HK$202.6M).
Long Term Liabilities: 455's short term assets (HK$577.4M) exceed its long term liabilities (HK$145.7M).
Debt to Equity History and Analysis
Debt Level: 455 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 455's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 455 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 455 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 55.5% each year.
Discover healthy companies
Dividend
What is Tianda Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
1.27%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 455's dividend (1.27%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.76%).
High Dividend: 455's dividend (1.27%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.89%).
Stability and Growth of Payments
Stable Dividend: 455 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 455 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 455 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: 455 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
13.3yrs
Average board tenure
CEO
Alan Fang (52 yo)
5.33yrs
Tenure
HK$60,000
Compensation
Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...
Board Members
Experienced Board: 455's board of directors are seasoned and experienced ( 13.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Tianda Pharmaceuticals Limited's employee growth, exchange listings and data sources
Key Information
- Name: Tianda Pharmaceuticals Limited
- Ticker: 455
- Exchange: SEHK
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$438.609m
- Shares outstanding: 2.15b
- Website: https://www.tiandapharma.com
Number of Employees
Location
- Tianda Pharmaceuticals Limited
- CITIC Tower
- 24th Floor
- Central
- Hong Kong
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/24 00:00 |
| End of Day Share Price | 2022/06/24 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.